98.7% HPLC
Péptido
Retatrutide
★★★★★ 4.9 · In stock
$ 1,500.00
Presentation
5 mg $ 1,500.00
10 mg $ 2,800.00
30 mg $ 6,900.00
Verifiable COA
Express shipping
Third-party tested
Description +
≈24%
Largest mean body-weight reduction among incretin compounds in published clinical research12 mg · 48 wk · Jastreboff, NEJM 2023
Purity ≥98.7% HPLCFormat Lyophilized powderVial 3 mlResearch use only
Dose response over time (research reference)
Percent change in body weight over 48 weeks by dose arm (Phase 2 trial, Jastreboff, NEJM 2023). Select an arm to highlight its curve and see its reduction over time:
−8.7%body-weight change at 48 wk · 1 mg
−16.3%body-weight change at 48 wk · 4 mg (initial dose 2 mg)
−17.8%body-weight change at 48 wk · 4 mg (initial dose 4 mg)
−21.7%body-weight change at 48 wk · 8 mg (initial dose 2 mg)
−23.9%body-weight change at 48 wk · 8 mg (initial dose 4 mg)
−24.2%body-weight change at 48 wk · 12 mg (initial dose 2 mg)
| Week | 4 | 12 | 24 | 36 | 48 |
|---|---|---|---|---|---|
| Δ weight | −3.2% | −5.2% | −7.0% | −7.8% | −8.7% |
| Week | 4 | 12 | 24 | 36 | 48 |
|---|---|---|---|---|---|
| Δ weight | −4.6% | −9.0% | −12.6% | −14.6% | −16.3% |
| Week | 4 | 12 | 24 | 36 | 48 |
|---|---|---|---|---|---|
| Δ weight | −5.2% | −10.4% | −14.0% | −16.2% | −17.8% |
| Week | 4 | 12 | 24 | 36 | 48 |
|---|---|---|---|---|---|
| Δ weight | −5.0% | −11.8% | −16.6% | −19.6% | −21.7% |
| Week | 4 | 12 | 24 | 36 | 48 |
|---|---|---|---|---|---|
| Δ weight | −5.2% | −13.2% | −17.6% | −21.0% | −23.9% |
| Week | 4 | 12 | 24 | 36 | 48 |
|---|---|---|---|---|---|
| Δ weight | −5.0% | −12.2% | −17.2% | −21.2% | −24.2% |
Curves approximated from the published figure; 48-week values are the reported LS-mean endpoints.
Research reference only — data from a published clinical trial (Phase 2). Not dosing guidance for human use. MVLabs products are for in-vitro research use only.
Overview
Retatrutide is an investigational peptide currently being studied in metabolic research. It is designed as a triple receptor agonist, simultaneously interacting with three key pathways involved in metabolic regulation:
- GLP-1 receptor (Glucagon-Like Peptide-1)
- GIP receptor (Glucose-Dependent Insulinotropic Polypeptide)
- Glucagon receptor
Because it engages all three pathways simultaneously, retatrutide is often referred to in scientific literature as a "triple agonist." This compound remains under clinical investigation and is not approved as a pharmaceutical product.
Research applications
- Metabolic regulation and energy balance mechanisms
- Glucose homeostasis and insulin secretion research
- Appetite and satiety signaling pathway studies
- Obesity and metabolic disorder research models
- Triple receptor agonist pharmacology and receptor selectivity studies
- Comparison with single and dual agonist GLP-1/GIP compounds
Research protocol reference
Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:
Starting dose0.5 mg
MaintenanceUp to 8 mg
FrequencyOnce weekly
Triple GLP-1/GIP/glucagon agonist. Start low and titrate up every 2–4 weeks. Do not exceed 8 mg/week.
Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.
Presentations & dosing: vial size varies by product. See the reconstitution guide in the Academy and use the calculator to convert your dose into exact units.
Open the calculator →Comparative research data
In published clinical research, retatrutide produced the largest mean body-weight reduction among the leading incretin-based compounds. The figures below come from separate trials (not head-to-head):
Retatrutide12 mg · 48 wk
~24%
Tirzepatide15 mg · 72 wk
~22.5%
Semaglutide2.4 mg · 68 wk
~15%
Approximate mean body-weight reductions from published trials (Jastreboff et al., NEJM 2022–2023; Wilding et al., NEJM 2021), shown for research reference only — separate studies, not direct comparisons.
Handling & storage
Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023. nejm.org
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. nejm.org
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021. nejm.org
Research use only. Research-grade, high-purity material (≥98.7% HPLC) supplied strictly for laboratory and analytical purposes. Not for human or animal consumption; not a drug or dietary supplement; not approved by the FDA, EMA or other agencies. To be handled only by qualified professionals in appropriate facilities, under all applicable laws. A certificate of analysis may be available on request.
Specifications +
| Purity (HPLC) | ≥ 98.7% |
| Form | Lyophilized |
| Category | Péptido |
| Storage | -20 °C, no light |
| SKU | 8209021730931 |
Reconstitution +
Reconstitute with bacteriostatic water and use our reconstitution calculator to convert your target dose into syringe units.
Certificate (COA) +
Each batch includes a verifiable certificate of analysis at /verify using the product code.
Tool
Reconstitution & dosing calculator
Convert your target dose into syringe units for this compound, on its dedicated page.
You may also need
Complete your protocol
Academy
Guides & articles
How to Reconstitute a Peptide: A Simple Step-by-Step Guide
Semaglutide: Complete Research Guide
Guía Completa: Comprar Péptidos para Investigación en México 2026
Retatrutide vs Semaglutide vs Tirzepatide: Comparativa para Investigación Metabólica
Qué es Retatrutide: Guía Completa del Péptido Triple Agonista
⚠ Solo para investigación (RUO). Compuesto liofilizado de grado investigación para uso in vitro únicamente. No aprobado para uso humano o veterinario. Venta a investigadores calificados. +18.